Clinical Cases in HER2+ Breast Cancer

With the clearance of an investigational new drug application for BTX-9341 from the FDA, a phase 1 trial will evaluate the agent in HR-positive/HER2-negative breast cancer.

In season 4, episode 2 of Targeted Talks, Sara A. Hurvitz, MD, discusses key advances in the HER2-positive breast cancer space and interesting ongoing research, namely trastuzumab deruxtecan.

Finalized breast cancer screening recommendations from the United States Preventive Services Task Force suggest women aged 40 to 74 should get a mammogram every other year.

In season 3, episode 8 of Targeted Talks, Christie J. Hilton, DO, discusses treating first- and second-line HER2-positive breast cancer.

Trastuzumab-strf, a biosimilar of trastuzumab, has received FDA approval for treating HER2-overexpressing breast cancer and metastatic gastric cancer.

New data from the DESTINY-Breast06 trial indicate that trastuzumab deruxtecan could become a new standard of care for patients with HER2-low and HER2-ultralow metastatic breast cancer.